INSIDER
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Alerts on Telegram

Congress trades and big insider sales, sent the day they're filed. Free.

Open in Telegram
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

Robinhood Chain…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyTelegram alerts
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Alerts on Telegram

Congress trades and big insider sales, sent the day they're filed. Free.

Open in Telegram
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyTelegram alerts
03 · Corporate insiders

Form 4 filings

Officers, directors and 10% owners must report trades within two business days on SEC Form 4. INSIDER parses each filing's XML from EDGAR. By default only discretionary open-market purchases and sales are shown; grants, option exercises and tax withholding are one click away.

Form 4 transactions

Cluster activity · 60d

Most active filers

Companies with the most Form 4 filings
Data sources
SEC Form 41m ago
House PTR1m ago
SEC 13F31s ago
Robinhood Chain30s ago

Most active filers · 30d

  1. 01Kurtz George0B / 217S · 10 late217 trades$54.77M
  2. 02SPSaba Capital Management, L.P.55B / 21S · 3 late76 trades$25.87M
  3. 03ATAdair Kathleen Theresa52B / 0S · 52 late52 trades$18K
  4. 04AJAllaire Jeremy0B / 50S50 trades$4.26M
  5. 05CFCheng Chi Fung0B / 42S42 trades$15.33M
  6. 06RARothblatt Martine A0B / 33S33 trades$5.50M
  7. 07RJRubinstein Julie0B / 32S32 trades$5.55M
  8. 08LBLeach Bryan0B / 30S30 trades$7.97M
  9. 09AOAtay Oguzhan0B / 30S30 trades$7.55M
  10. 10JDJenkins William D Jr0B / 30S30 trades$13.38M

Cluster activity · 60d

  1. SELLDRDDRDGOLD LTDOct 27 – Oct 2710 insiders$1.23M
  2. BUYMTDRMatador Resources CoNov 5 – Nov 98 insiders$625K
  3. SELLFERGFerguson Enterprises Inc. /DE/Oct 12 – Oct 167 insiders$7.38M
  4. SELLSYMSymbotic Inc.Oct 26 – Nov 27 insiders$1.98M
  5. BUYUPBDUPBOUND GROUP, INC.Nov 2 – Nov 37 insiders$1.34M
  6. SELLIBEXIBEX LtdSep 14 – Sep 166 insiders$2.01M
  7. SELLARQQArqit Quantum Inc.Oct 2 – Oct 136 insiders$369K
  8. BUYBBTBeacon Financial CorpOct 26 – Oct 306 insiders$274K

Form 4 transactions

66,706 records
Side
allbuysell
Score
any≥ 30≥ 50≥ 70
Sort
Newest disclosedNewest executedInsider ScoreValue
Include
grants & admin
ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
12
DC
Dec Timothy CSenior Vice-President & CFO
SUPNSUPERNUS PHARMACEUTICALS, INC.
Other acquisition or disposition
J—
40.0K sh
Nov 2, 2026
Page 80 of 1668
← PrevNext →
Nov 4, 2026
traded Nov 2, 2026
+2d
SEC Form 4

Evidence

12
MF
Mottola FrankSVP, Chief Tech. Ops. Officer
SUPNSUPERNUS PHARMACEUTICALS, INC.
Other acquisition or disposition
J—
3,375 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

12
KA
Khattar Jack A.Director, President, CEO
SUPNSUPERNUS PHARMACEUTICALS, INC.
Other acquisition or disposition
J—
200.0K sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

12
GG
Gemayel GeorgesDirector
SUPNSUPERNUS PHARMACEUTICALS, INC.
Other acquisition or disposition
J—
6,847 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

12
GG
Gemayel GeorgesDirector
SUPNSUPERNUS PHARMACEUTICALS, INC.
Other acquisition or disposition
J—
12.4K sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

12
WC
Woods Todd CharlesChief Commercial Officer
WAYWaystar Holding Corp.
Tax withholding
F$111K
4,042 sh
Nov 3, 2026Nov 4, 2026
traded Nov 3, 2026
+1dSEC Form 4

Evidence

12
TD
Tsao DavidDirector, Chief Technology Officer
BLLNBillionToOne, Inc.
Open-market sale · 10b5-1 plan
SELL$23K
208 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

12
CJ
Comly Barbara J.EVP, GC & Corporate Secretary
MIAXMIAMI INTERNATIONAL HOLDINGS, INC.
Open-market sale · 10b5-1 plan
SELL$819K
23.3K sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

12
RJ
Rubin JonathanSVP, Chief Medical Officer
SUPNSUPERNUS PHARMACEUTICALS, INC.
Other acquisition or disposition
J—
25.0K sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

12
RJ
Rubin JonathanSVP, Chief Medical Officer
SUPNSUPERNUS PHARMACEUTICALS, INC.
Other acquisition or disposition
J—
20.0K sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

12
RJ
Rubin JonathanSVP, Chief Medical Officer
SUPNSUPERNUS PHARMACEUTICALS, INC.
Other acquisition or disposition
J—
1,250 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

12
MF
Mottola FrankSVP, Chief Tech. Ops. Officer
SUPNSUPERNUS PHARMACEUTICALS, INC.
Other acquisition or disposition
J—
19.5K sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

12
MF
Mottola FrankSVP, Chief Tech. Ops. Officer
SUPNSUPERNUS PHARMACEUTICALS, INC.
Other acquisition or disposition
J—
25.0K sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

12
FL
Flavin LisaSenior VP & CCO
EMREMERSON ELECTRIC CO
Tax withholding
F$125K
750 sh
Nov 3, 2026Nov 4, 2026
traded Nov 3, 2026
+1dSEC Form 4

Evidence

12
SS
Singh SumitDirector, Chief Executive Officer
CHWYChewy, Inc.
Open-market sale · 10b5-1 plan
SELL$492K
23.0K sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

12
BC
Barlow CarroleeDirector
SUPNSUPERNUS PHARMACEUTICALS, INC.
Other acquisition or disposition
J—
9,305 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

12
RJ
Rubin JonathanSVP, Chief Medical Officer
SUPNSUPERNUS PHARMACEUTICALS, INC.
Other acquisition or disposition
J—
3,500 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

12
GG
Gemayel GeorgesDirector
SUPNSUPERNUS PHARMACEUTICALS, INC.
Other acquisition or disposition
J—
7,296 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

12
RJ
Rubin JonathanSVP, Chief Medical Officer
SUPNSUPERNUS PHARMACEUTICALS, INC.
Other acquisition or disposition
J—
13.5K sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

12
MF
Mottola FrankSVP, Chief Tech. Ops. Officer
SUPNSUPERNUS PHARMACEUTICALS, INC.
Other acquisition or disposition
J—
2,500 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

12
BP
Bhatt Padmanabh P.Sr. VP of IP, CSO
SUPNSUPERNUS PHARMACEUTICALS, INC.
Other acquisition or disposition
J—
3,375 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

12
KA
Khattar Jack A.Director, President, CEO
SUPNSUPERNUS PHARMACEUTICALS, INC.
Other acquisition or disposition
J—
400.0K sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

12
MF
Mottola FrankSVP, Chief Tech. Ops. Officer
SUPNSUPERNUS PHARMACEUTICALS, INC.
Other acquisition or disposition
J—
14.0K sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

12
MF
Mottola FrankSVP, Chief Tech. Ops. Officer
SUPNSUPERNUS PHARMACEUTICALS, INC.
Other acquisition or disposition
J—
20.0K sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

12
DC
Dec Timothy CSenior Vice-President & CFO
SUPNSUPERNUS PHARMACEUTICALS, INC.
Other acquisition or disposition
J—
3,375 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

12
SL
Sloan Lindsay LVP & Chief Accounting Officer
CMCCOMMERCIAL METALS Co
Gift
G—
200 sh
Nov 3, 2026Nov 4, 2026
traded Nov 3, 2026
+1dSEC Form 4

Evidence

12
HM
Hudson Frederick M.Director
SUPNSUPERNUS PHARMACEUTICALS, INC.
Other acquisition or disposition
J—
6,293 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

12
KA
Khattar Jack A.Director, President, CEO
SUPNSUPERNUS PHARMACEUTICALS, INC.
Other acquisition or disposition
J—
300.0K sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

12
BP
Bhatt Padmanabh P.Sr. VP of IP, CSO
SUPNSUPERNUS PHARMACEUTICALS, INC.
Other acquisition or disposition
J—
2,500 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

12
KA
Khattar Jack A.Director, President, CEO
SUPNSUPERNUS PHARMACEUTICALS, INC.
Other acquisition or disposition
J—
250.0K sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

12
GG
Gemayel GeorgesDirector
SUPNSUPERNUS PHARMACEUTICALS, INC.
Other acquisition or disposition
J—
6,036 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

12
DC
Dec Timothy CSenior Vice-President & CFO
SUPNSUPERNUS PHARMACEUTICALS, INC.
Other acquisition or disposition
J—
50.0K sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

12
DC
Dec Timothy CSenior Vice-President & CFO
SUPNSUPERNUS PHARMACEUTICALS, INC.
Other acquisition or disposition
J—
40.0K sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

12
DC
Dec Timothy CSenior Vice-President & CFO
SUPNSUPERNUS PHARMACEUTICALS, INC.
Other acquisition or disposition
J—
25.0K sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

12
DC
Dec Timothy CSenior Vice-President & CFO
SUPNSUPERNUS PHARMACEUTICALS, INC.
Other acquisition or disposition
J—
85.0K sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

12
DC
Dec Timothy CSenior Vice-President & CFO
SUPNSUPERNUS PHARMACEUTICALS, INC.
Other acquisition or disposition
J—
3,000 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

12
CP
Coghlan John PhilipDirector
LIFLife360, Inc.
Open-market sale · 10b5-1 plan
SELL$66K
1,433 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

12
CP
Coghlan John PhilipDirector
LIFLife360, Inc.
Open-market sale · 10b5-1 plan
SELL$83K
1,841 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

12
KA
Khattar Jack A.Director, President, CEO
SUPNSUPERNUS PHARMACEUTICALS, INC.
Other acquisition or disposition
J—
19.3K sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence

12
FR
Fenimore Christopher R.EVP Finance CFO
REGNREGENERON PHARMACEUTICALS, INC.
Gift
G—
15 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC Form 4

Evidence